Orlowski Robert Z
The Department of Medicine and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA.
Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339.
Inhibitors of the proteasome have long been used in studies of protein turnover, but in a notable example of successful translational research they have made the leap from the laboratory into the clinical arena. The proteasome inhibitor bortezomib (VELCADE, formerly known as PS-341), has recently been approved in the United States for treatment of patients with multiple myeloma who have received at least two prior therapies, and have demonstrated disease progression on their last therapy. Furthermore, studies of this agent in other hematologic malignancies and solid tumors are underway, and other proteasome inhibitors for clinical use are under development as well. This chapter provides the reader with guidelines for the optimal clinical administration of VELCADE for its currently approved indication, as well as some suggestions for subsequent management of treatment-related events in these patients.
蛋白酶体抑制剂长期以来一直用于蛋白质周转的研究，但作为成功转化研究的一个显著例子，它们已从实验室跃入临床领域。蛋白酶体抑制剂硼替佐米（万珂，原名PS-341）最近在美国被批准用于治疗接受过至少两种先前治疗且在最后一次治疗中出现疾病进展的多发性骨髓瘤患者。此外，正在对该药物在其他血液系统恶性肿瘤和实体瘤中的研究进行中，其他用于临床的蛋白酶体抑制剂也在研发中。本章为读者提供了关于万珂目前已批准适应症的最佳临床给药指南，以及对这些患者后续治疗相关事件管理的一些建议。
